Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Debt / Cv 5.0%
-
Market price (% of par)
-
40.0%
-
Total 13F principal
-
$45,563,508
-
Principal change
-
+$12,445,575
-
Total reported market value
-
$15,909,159
-
Number of holders
-
7
-
Value change
-
+$1,708,322
-
Number of buys
-
4
Institutional Holders of Accelerate Diagnostic - Cv 5.0% as of Q2 2024
As of 30 Jun 2024,
Accelerate Diagnostic - Cv 5.0% was held by
7 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$45,563,508
in principal (par value) of the bond.
The largest 7 bondholders included
Indaba Capital Management, L.P., Royal Bank of Canada, WOLVERINE ASSET MANAGEMENT LLC, Bruce & Co., Inc., PenderFund Capital Management Ltd., UBS ASSET MANAGEMENT AMERICAS LLC, and INGALLS & SNYDER LLC.
This page lists
7
institutional bondholders reporting positions
for the Q2 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.